The use of brincidofovir for the treatment of mixed dsDNA viral infection

J Clin Virol. 2016 Oct:83:1-4. doi: 10.1016/j.jcv.2016.07.021. Epub 2016 Aug 4.

Abstract

Double-stranded DNA (dsDNA) viral infections constitute a major complication following solid organ and stem cell transplantation. Few therapeutic options are currently available for the treatment of such infections in highly immunocompromised hosts. Brincidofovir is an oral investigational drug with broad antiviral activity against dsDNA viruses in vitro, but clinical experience is limited. Here we report a young female who developed a mixed infection with adenovirus, cytomegalovirus, Epstein-Barr virus and BK polyomavirus after an allogeneic stem cell transplant, and was successfully treated with brincidofovir.

Keywords: Adenovirus; BK virus; Brincidofovir; CMX001; Cytomegalovirus; Epstein–Barr virus.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • BK Virus
  • Coinfection* / drug therapy
  • Coinfection* / virology
  • Cytomegalovirus
  • Cytosine / analogs & derivatives*
  • Cytosine / therapeutic use
  • DNA Virus Infections* / drug therapy
  • DNA Virus Infections* / virology
  • Fatal Outcome
  • Female
  • Herpesvirus 4, Human
  • Humans
  • Immunocompromised Host
  • Organophosphonates / therapeutic use*
  • Stem Cell Transplantation
  • Viral Load
  • Young Adult

Substances

  • Antiviral Agents
  • Organophosphonates
  • brincidofovir
  • Cytosine